Logo Image
Opinion|Videos|August 6, 2024

Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

Episodes in this series

Video content above is prompted by the following:

  • A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses. What do you believe accounts for this high number of patients who are not responding adequately?
    • Patients have to come in for first 3 doses because this a biologic. Is this preferred? Is there a burden on these patients?
    • Said prescription targets the IgE pathway, but a significant percentage of patients have IgG antibodies as part of their disease pathophysiology. What do you do in your patients who do not respond to this prescription?
    • Why is it imperative to develop new treatments that target the IgG pathway?

Related Content